Clinical trials: Tumor Markers, Biological
Metastatic Ovarian Cancer
Prognostic and Predictive Value of HE4 Biomarker in Metastatic Ovarian Cancer
HE4 is a new marker that could improve the detection of ovarian cancer. The HE4 assay may have an advantage over the CA-125 assay in that it is less frequently positive in patients with non malignant disease.
- Trial name
- Meta-Four (NCT01768156)
- Testing
- Experimental arm
- Where
- 2 sites in France
- Volunteers
- 101 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Cancer Survivors, Cardiotoxicity
In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors
The BREATHS trial aims to investigate whether overnight in-bedroom air filtration reduces inflammation and cardiac biomarkers in adult survivors of cancer who are at high risk for cardiovascular complications.
- Conditions
- Cancer Survivors, Cardiotoxicity, Cardiovascular Toxicity Induced by Antitumoral Drugs
- Trial name
- BREATHS (NCT06778122)
- Testing
- High efficiency particulate air filtration system (nightly administration), High efficiency particulate air filtration system (nightly and daily administration)
- Where
- 3 sites in Spain
- Volunteers
- 10 people
- Sponsor
- University College, London
Colorectal Cancer
Precision-MRD: Prospective Observational Study of Biomarker-directed Systemic Therapy for Colorectal Cancer Patients With Minimal Residual Disease
The goal of this clinical research study is to learn about the effects of biomarkertargeted therapy on ctDNA in patrticipants with CRC and MRD. This is an observational study.
- Trial name
- NCT06878131
- Testing
- Colorectal Cancer
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer Metastatic, Microsatellite Instability-High Colorectal Cancer
Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM)
The Keynote 117 phase III trial demonstrated the superiority of pembrolizumab (anti-PD1 monoclonal antibody) versus chemotherapy +/- targeted therapy in first-line treatment of dMMR/MSI metastatic colorectal cancer (mCRC).
- Trial name
- CORESIM (NCT06353854)
- Where
- 20 sites in France
- Volunteers
- 600 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease
A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.
- Conditions
- Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease, Early Stage Parkinson's Disease
- Trial name
- NCT07630545
- Testing
- MTX325
- Where
- 18 sites in Australia, France and 2 more
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Mission Therapeutics
Diabetes Mellitus, Adult-Onset, Diabetes Complications
Pancreatic Cancer Can be Detected by Adrenomedullin in New Onset Diabetes Patients
Pancreatic Cancer is a leading cause of cancer-related death. To date, only one fifth of patients at diagnosis is presented resectable because the diagnosis is often delayed making the 5-year survival of this disease globally…
- Conditions
- Diabetes Mellitus, Adult-Onset, Diabetes Complications, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasm
- Trial name
- PaCANOD (NCT02456051)
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- University of Roma La Sapienza
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics?
Ki-67 is used as a marker for determination of the proliferative activity in solid tumors. The use within hemato-oncological malignancies is limited.
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm
- Trial name
- NCT04517175
- Testing
- Flow cytometry
- Volunteers
- 300 people
- Sponsor
- Maastricht University
PEComa, Hemangioma
Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors
PEComa is rare tumor affecting particularly patients with Tuberous Sclerosis. Biological similarities were seen between PEComa and infantile hemangioma.
- Trial name
- PEC-Hem (NCT02334930)
- Testing
- Biopsy
- Where
- France
- Volunteers
- 13 people
- Sponsor
- University Hospital, Bordeaux
Recurrent Malignant Glioma
Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma
Malignant glioma are the most common and aggressive primary brain tumors in adults. Despite advances in multimodal treatment including surgery, radiation and chemotherapy, most patients have a dismal prognosis of 9-15 months…
- Trial name
- AVIRMA01-09 (NCT01144988)
- Testing
- Bevacizumab / Irinotecan
- Where
- 2 sites in Austria
- Volunteers
- 35 people
- Sponsor
- Medical University Innsbruck
Periodontal Disease, Gingivitis and Periodontal Diseases
Hippo Signaling Pathway Proteins in Gingival Crevicular Fluid of Individuals With Periodontal Disease
Periodontal disease is a chronic inflammatory condition of the tooth-supporting tissues in which the host inflammatory response drives the destruction of alveolar bone and periodontal attachment.
- Conditions
- Periodontal Disease, Gingivitis and Periodontal Diseases, Biomarker Discovery and Validation, Pathways
- Trial name
- BYHN-GCF-HIPPO (NCT07759466)
- Testing
- ELISA Biomarker Analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Inonu University
Metastatic Colorectal Cancer
Biomarker - Panitumumab Response With KRAS Wild Type MCC
This is an exploratory study in which all eligible subjects are given Panitumumab according to the dose and schedule approved by Health Canada.
- Trial name
- NCT00853931
- Testing
- Panitumumab
- Where
- 3 sites in Canada
- Volunteers
- 52 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer, Cardiovascular Complications
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving bevacizumab may help doctors learn more about changes that occur in DNA and identify biomarkers related to high blood pressure.
- Conditions
- Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01096381
- Testing
- laboratory biomarker analysis, questionnaire administration
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Obesity, Solid Neoplasm
Weight Management in Obese Cancer Patients During Curative Active Treatment
This is a feasibility study intervention to fifty cancer patients with obesity and with newly diagnosed stage II-IV solid tumors undergoing curative treatment recruited at the Catalan Institute of Oncology (ICO) in L'Hospitalet…
- Conditions
- Obesity, Solid Neoplasm, Stage II-IV, Curative Treatment
- Trial name
- CANOBESE (NCT07058207)
- Testing
- Multimodal weight management program
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Institut d'Investigació Biomèdica de Bellvitge
Stomach Neoplasms
Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma
The trial aims to evaluate the efficacy and safety of adding nimotuzumab to irinotecan after failure of first-line treatment in recurrent or metastatic gastric adenocarcinoma with overexpression of EGFR, and search for the…
- Trial name
- NIEGA (NCT03400592)
- Testing
- Irinotecan, nimotuzumab
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Peking University
Metastatic Nasopharyngeal Cancer
Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in
This study is the first phase II study of 177Lu-DOTA0-Tyr3-Octreotate in metastatic NPC. Patients whom have failed 2 or more lines of therapy or exhausted standard therapy and are avid on 68Ga-DOTATATE imaging will be eligible to…
- Trial name
- SG-AAA-II-01 (NCT05198479)
- Testing
- 77 Lu-DOTA0-Tyr3-Octreotate
- Where
- 2 sites in Singapore
- Volunteers
- 25 people
- Sponsor
- National Cancer Centre, Singapore
Oral Potentially Malignant Disorders, Oral Lichen Planus
Salivary IL-8 and Serum IL-6 as Biomarkers for Oral Potentially Malignant Disorders in Smokers and Never-Smokers
The goal of this observational study is to learn whether two inflammatory proteins, interleukin-8 (IL-8) measured in saliva and interleukin-6 (IL-6) measured in blood serum, can help distinguish adults with oral potentially…
- Conditions
- Oral Potentially Malignant Disorders, Oral Lichen Planus, Oral Leukoplakia, Oral Squamous Cell Carcinoma
- Trial name
- NCT07915570
- Testing
- Salivary IL-8 and Serum IL-6 Measurement
- Where
- Egypt
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- British University In Egypt
Neuroendocrine Tumors
Biomarker Study in Pancreatic Neuroendocrine Tumours
The biology of pancreatic neuroendocrine tumors can change during the disease course. This evolution of disease can manifest through increases in tumor proliferation rate, resistance to medical therapy and/or a change in tumor…
- Trial name
- PROGRESS (NCT03130205)
- Testing
- Core Needle Biopsy, Computed Tomography, 18F-FDG-PET
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Uppsala University
Pancreatic Neoplasms, DNA Methylation
Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples
The goal of this observational study is to test in patients with cystic tumor of pancreas. The main questions it aims to answer are: Screening of molecular diagnostic markers for pancreatic cystic tumors by cfDNA methylation…
- Conditions
- Pancreatic Neoplasms, DNA Methylation, Proteome
- Trial name
- NCT05737953
- Testing
- cfDNA methylation sequencing and proteome analysis
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhaoshen Li
Non-Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors
A pilot study evaluating baseline and on-treatment changes in tumor fraction (TFx) in peripheral blood in patients with NSCLC and RCC being treated with checkpoint inhibitor therapy as part of standard of care.
- Trial name
- NCT06630429
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Non-Small Cell Lung Cancer, Radiation-Induced Cardiac Disease
Biomarker Testing to Predict Radiation-Related Heart Disease in Lung Cancer Patients
The study will measure serum Pro-N-Cadherin and NT-proBNP (pro B-type natriuretic peptide) levels in adults with non-small cell lung cancer receiving hypofractionated radiation therapy and evaluate whether these biomarkers…
- Trial name
- NCT07869329
- Testing
- Serum Pro-N-Cadherin Biomarker Assessment, Echocardiogram
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Duke University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.